Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS CURRENT ASSETS Cash Investments in related entity Note receivable, net of premium Prepaids and other current assets Total Current Assets [Assets, Current] OTHER ASSETS Other assets Licenses, net of amortization TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Advances from related party Total Current Liabilities [Liabilities, Current] TOTAL LIABILITIES [Liabilities] STOCKHOLDERS' EQUITY Preferred stock, $0.001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025 Common stock, $0.001 par value, 25,000,000 shares authorized; 3,701,668 issued and 3,696,668 outstanding at March 31, 2026 and December 31, 2025, respectively Additional paid-in capital Accumulated deficit Treasury stock, at cost, 5,000 shares as of March 31, 2026 and December 31, 2025. [Treasury Stock, Common, Value] TOTAL STOCKHOLDERS' EQUITY [Equity, Attributable to Parent] Non-controlling interest TOTAL EQUITY ATTRIBUTABLE TO CMTH [Equity, Including Portion Attributable to Noncontrolling Interest] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Common stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, cost Preferred stock, shares par value Preferred stock, shares authorized UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Revenues Cost of revenues Gross profit [Gross Profit] OPERATING EXPENSES Research and development Selling, general and administrative Amortization of patent costs TOTAL EXPENSES [Operating Expenses] Operating loss [Operating Income (Loss)] OTHER INCOME/(EXPENSE) Interest income Total other income [Nonoperating Income (Expense)] LOSS BEFORE PROVISION FOR INCOME TAXES [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Provision for income taxes NET LOSS [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Net income attributable to non-controlling interest NET LOSS ATTRIBUTABLE TO CMTH [Net Income (Loss) Attributable to Parent] NET LOSS PER SHARE - BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Amortization of intangible assets Amortization of note receivable premium Changes in assets and liabilities: Inventory [Increase (Decrease) in Inventories] Prepaids and other current assets [Increase (Decrease) in Other Current Assets] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses Net cash used in operating activities [Cash Provided by (Used in) Operating Activity, Including Discontinued Operation] CASH FLOWS FROM INVESTING ACTIVITIES: Issuance of note receivable [Payments to Acquire Notes Receivable] Investment in related entity [Payments to Acquire Investments] Net cash used in investing activities [Cash Provided by (Used in) Investing Activity, Including Discontinued Operation] CASH FLOWS FROM FINANCING ACTIVITIES: Contribution from minority member Purchase of treasury stock [Payments for Repurchase of Common Stock] Proceeds from sale of common stock and warrants, net of issuance costs Net cash provided in financing activities [Cash Provided by (Used in) Financing Activity, Including Discontinued Operation] NET CHANGE IN CASH [Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation] BEGINNING CASH BALANCE ENDING CASH BALANCE SUPPLEMENTAL CASH FLOW INFORMATION: Cash payments for interest Cash payments for income taxes UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Treasury Stock Parent [Member] Noncontrolling Interest Balance, shares [Shares, Issued] Balance, amount Proceeds from exercise of warrants, shares Proceeds from exercise of warrants, amount Offering costs Purchase of treasury shares Stock-based compensation [APIC, Share-Based Payment Arrangement, Increase for Cost Recognition] Net loss Contribution by minority member Balance, shares Balance, amount Insider Trading Arrangements Insider Trading Arragement [Line Items] Rule 10b5-1 Arragement Adopted [Flag] Rule 10b5-1 Arragement Treatment [Flag] Non Rule 10b5-1 Arragement Adopted [Flag] Non Rule 10b5-1 Arragement Treatment [Flag] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] LICENSING AGREEMENTS LICENSING AGREEMENTS [LICENSING AGREEMENTS] STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY Equity [Text Block] NOTE RECEIVABLE NOTE RECEIVABLE Financing Receivables [Text Block] RELATED PARTY INVESTMENT RELATED PARTY INVESTMENT Related Party Transactions Disclosure [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] Organization Operating Segments and Related Disclosures Risks and Uncertainties Use of Estimates Basis of Presentation Non-Controlling Interest Concentration Risks Cash Equivalents Accounts and Notes Receivable Inventories Fair Value of Financial Instruments Intangible Assets Impairment Derivative Liabilities Revenue Research and Development Stock-Based Compensation Basic and Diluted Income (Loss) Per Share Accounting Pronouncements Not Yet Adopted Schedule of licensing agreements Schedule of stock option activity Schedule of assumptions used in calculation of fair value of warrants Schedule of warrant activity Financial Instrument [Axis] Option [Member] Warrants [Member] FDIC insured amount Research and development Deferred revenue Anti-dilutive securities Indefinite-Lived Intangible Assets [Axis] Licensing Agreements [Member] Assets, beginning balance [Finite-Lived Intangible Assets, Gross] Addition of new assets Amortization Assets, ending balance Accumulated amortization, beginning balance [Accumulated amortization, beginning balance] Addition of new assets, accumulated amortization Increase in amortization Accumulated amortization, ending balance Finite-Lived Intangible Assets by Major Class [Axis] Product Or Service Axis Subsegments Axis Subsidiary Sale Of Stock Axis Plan Name Axis Patents [Member] ImmCelz Patent [Member] Option Warrant [Member] Jadi Cell [Member] License Agreement [Member] EDI Patent [Member] StemSpine LLC [Member] IND [Member] Pyment for license fees Number of shares Additional CMH payment Obligation due under agreement through the issuance of common stocks Payment for clinical trial Common stock value Common stock, shares Patents gross Total obligation under the agreement Discount rate Initial payment of obligation Balance of obligation, description Remaining portion of obligation Amortization expenses Amortization expenses [Amortization expenses] Common stock shares Interest rate Carrying value of patent [Other Intangible Assets, Net] Carrying value of patent Exercise price Expiration period of finite-lived intangible assets Description of payment on conversion basis Description for the consecutive trading days Amortization [Depreciation, Depletion and Amortization, Nonproduction] Initial payment Payments upon dosing of the first patient in Phase 3 clinical trial Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial Payments upon completion of the IRB clinical trial Payments in the event of commercialization of technology Stock option, outstanding at the begining [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number] Stock option, issued Stock option, exercised Stock option, expired Stock option, outstanding at the ending Stock option, vested Weighted average exercise price, outstanding beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Weighted average exercise price, issued Weighted average exercise price, exercised Weighted average exercise price, expired Weighted average exercise price, outstanding ending Weighted average exercise price, vested Weighted average life remaining, outstanding beginning Weighted average life remaining, outstanding ending Weighted average life remaining, vested Related Party Transaction Axis Board of Directors [Member] Under the 2021 Plan [Member] Fair value of warrants Stock option, issued Stock-based compensation Option to purchase common shares Weighted average exercise price, issued Share-based compensation arrangement by share-based payment award, number of shares authorized Annual dividend yield Risk-free interest rate Expected volatility Expected life (years) Common stock price Warrants [Member] [Warrants [Member]] Warrants, outstanding beginning balance [Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number] Warrants, issued Warrants, exercises Warrants, outstanding ending balance Weighted average exercise price, outstanding issued Weighted average exercise price, outstanding exercises Weighted average life remaining, outstanding beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term] Weighted average life remaining, outstanding ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term] Warrants [Member] Warrant Exercise Inducement Agreements [Member] New Warrant [Member] Roth Capital Partners, LLC [Member] New Warrant #2 [Member] Share Repurchase Program [Member] Description of offering Reurchase of common stock, shares Common stock, shares authorized Warrants, outstanding Warrants issued to purchase Warrants to purchase common stock Warrant exercise price Increase and decrease to additional paid-in capital Net proceed from issuance of warrants Warrants exercise price Issued warrants to purchase shares to investors Reimbursed legal expenses Advisory fee percentage Title and Position [Axis] Short-Term Debt, Type [Axis] Subsequent Event Type Axis CEO [Member] Convertible Promissory Notes [Member] Convertible Promissory Notes Two [Member] Subsequent event [Member] Notes receivable face amount Proceed from notes receivable Original issue discount Other issuance costs Interest rate [Debt Instrument, Interest Rate During Period] Default interest rate Note maturity date Amortized premium Amount amortized to interest income Remaining premium balance Number of trading days Limited optional prepayment period Monthly equal payments Issued shares of restricted common stock Capital contribution commitment by parties Annual contribution by related party Carrying value of the investments Capital advance